wiki:Publications
Last modified 7 months ago Last modified on 01/22/17 15:48:36

Publications

2017

  1. Ronchini C, Brozzi A, Riva L, Luzi L, Gruszka AM, Melloni GEM, Scanziani E, Dharmalingam G, Mutarelli M, Belcastro V, Lavorgna S, Rossi V, Spinelli O, Biondi A, Rambaldi A, Lo-Coco F, di Bernardo D, Pelicci PG. PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.386.

2016

  1. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. Oncotarget. 2016 Oct 13. doi: 10.18632/oncotarget.12646.
  1. Carugo A*, Genovese G*, Seth S*, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, Akdemir KC, Bristow CA, Robinson FS, Tepper J, Sanchez N, Gupta S, Estecio MR, Giuliani V, Dellino GI, Riva L, Yao W, Di Francesco ME, Green T, D'Alesio C, Corti D, Kang Y, Jones P, Wang H, Fleming JB, Maitra A, Pelicci PG, Chin L, DePinhoRA, Lanfrancone L, Heffernan TP, Draetta GF. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 Jun 16. pii: S2211-1247(16)30661-1. doi: 10.1016/j.celrep.2016.05.063
  1. Bossi D*, Cicalese A*, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni GEM, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci PG, Lanfrancone L. In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discov. 2016 Jun;6(6):650-63. doi: 10.1158/2159-8290.CD-15-1200.
  1. Melloni GEM*, de Pretis S*, Riva L, Pelizzola M, Céol A, Costanza J, Müller H, Zammataro L. LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer. BMC Bioinformatics. 2016 Feb 9;17(1):80. doi: 10.1186/s12859-016-0935-7.

2015

  1. Cremona MA, Sangalli LM, Vantini S, Dellino GI, Pelicci PG, Secchi P, Riva L Peak shape clustering reveals biological insights. BMC Bioinformatics.2015, 16:349. DOI: 10.1186/s12859-015-0787-6
  1. de Pretis S, Kress T, Morelli MJ, Melloni GEM, Riva L, Amati B, Pelizzola M. INSPEcT: a Computational Tool to Infer mRNA Synthesis, Processing and Degradation Dynamics from RNA- and 4sU-seq Time Course Experiments. Bioinformatics (2015) 31 (17): 2829-2835. DOI: 10.1093/bioinformatics/btv288
  1. Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D, Bernard L, Pece S, Di Fiore PP, Fumagalli C, Barberis M, Spaggiari L, Pelicci PG, Riva L. Whole-exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype. Cancer Genet. 2015 Feb 20. DOI:10.1016/j.cancergen.2015.02.004
  1. Bodini M, Ronchini C, Giacò L, Russo A, Melloni GEM, Luzi L, Sardella D, Volorio S, Hasan SK, Ottone T, Lavorgna S, Lo-Coco F, Candoni A, Fanin R, Toffoletti E, Iacobucci I, Martinelli G, Cignetti A, Tarella C, Bernard L, Pelicci PG, and Riva L. The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. Blood. 2015 Jan 22;125(4):600-5. DOI 10.1182/blood-2014-05-576157

2014

  1. Mazzarella L, Riva L, Luzi L, Ronchini C, Pelicci PG. The Genomic and Epigenomic Landscapes of AML. Semin Hematol. 2014 Oct; 51(4):259-72. DOI: 10.1053/j.seminhematol.2014.08.007.
  1. Melloni GEM, Ogier AGE, de Pretis S, Mazzarella L, Pelizzola M, Pelicci PG, Riva L. DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. Genome Medicine 2014, 6:44, DOI: 10.1186/gm563

2013

  1. Riva L*, Ronchini C*, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GEM, Luzi L, Alcalay M, Dellino GI and Pelicci PG. Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups. Blood Cancer Journal (2013) 3, e147; DOI:10.1038/bcj.2013.46

2012

  1. Riva L*, Koeva M*, Yildirim F, Dinesh D, Mazor T, Pirhaji L, Duennwald ML, Fraenkel E. Polyglutamine Expanded Huntingtin Dramatically Alters the Genome-Wide Binding of HSF-1. Journal of Huntington’s Disease, Volume 1/Issue 1 (2012), DOI 10.3233/JHD-2012-120020.
  1. Riva L*, Luzi L*, Pelicci PG. Genomics of acute myeloid leukemia: the next generation. Frontiers in Molecular and Cellular Oncology, Front. Oncol. 2012;2:40. doi: 10.3389/fonc.2012.00040

2009

  1. Yu M*, Riva L*, Xie H, Schindler Y, Moran TB, Cheng Y, Yu D, Hardison R, Weiss MJ, Orkin SH, Bernstein BE, Fraenkel E, Cantor AB. Insights into GATA-1-Mediated Gene Activation versus Repression via Genome-wide Chromatin Occupancy Analysis. Mol Cell. 2009 Nov;36(4):682-695.
  1. Yeger-Lotem E*, Riva L*, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, Lindquist S, Fraenkel E. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nature Genetics. 2009 Mar;41(3):316-23.

*equally contribution